Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen says Nplate addresses medical needs

Amgen says Nplate addresses medical needs

8th June 2009

Amgen’s Nplate (romiplostim) addresses an unmet medical need for patients, the firm has stated.

The company discussed data of a study comparing the medication to the standard care in non-splenectomised adult patients with chronic immune thrombocytopenic purpura.

A low platelet count in the blood is a main characteristic of the condition, which can lead to serious bleeding events.

Patients who took Nplate gained a number of benefits in the study – including reduced bleeding, explained head haematology at the Hospital of the Justus-Liebig University in Germany Dr Mathias Rummel.

“Nplate is a unique treatment option that can help us better manage patients with chronic ITP ?. It increases platelet production and avoids immune suppression,” he commented.

The findings from the study were presented at the 14th congress of European Haematology Association yesterday (June 7th).

Last month, Amgen announced results of a survey that revealed a large number of oncologists and infectious disease specialists are worried about the damage an infection could cause to patients undergoing chemotherapy.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.